ORAVERSE Drug Patent Profile
✉ Email this page to a colleague
When do Oraverse patents expire, and what generic alternatives are available?
Oraverse is a drug marketed by Septodont Holding and is included in one NDA.
The generic ingredient in ORAVERSE is phentolamine mesylate. There are four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the phentolamine mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Oraverse
A generic version of ORAVERSE was approved as phentolamine mesylate by HIKMA on March 11th, 1998.
Summary for ORAVERSE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 110 |
| Clinical Trials: | 6 |
| Patent Applications: | 1,014 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ORAVERSE |
| What excipients (inactive ingredients) are in ORAVERSE? | ORAVERSE excipients list |
| DailyMed Link: | ORAVERSE at DailyMed |
Recent Clinical Trials for ORAVERSE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Cairo University | Phase 3 |
| sara nabil | Phase 3 |
| Dalhousie University | Phase 4 |
Pharmacology for ORAVERSE
| Drug Class | alpha-Adrenergic Blocker |
| Mechanism of Action | Adrenergic alpha-Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for ORAVERSE
US Patents and Regulatory Information for ORAVERSE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ORAVERSE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Try a Trial | ⤷ Try a Trial |
| Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Try a Trial | ⤷ Try a Trial |
| Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Try a Trial | ⤷ Try a Trial |
| Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Try a Trial | ⤷ Try a Trial |
| Septodont Holding | ORAVERSE | phentolamine mesylate | INJECTABLE;INJECTION | 022159-001 | May 9, 2008 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ORAVERSE
See the table below for patents covering ORAVERSE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Cyprus | 1107617 | ⤷ Try a Trial | |
| Japan | 2010280702 | STABILIZED FORMULATION OF ALPHA ADRENERGIC RECEPTOR ANTAGONISTS AND USE THEREOF | ⤷ Try a Trial |
| South Africa | 200209811 | Local anesthetic methods and kits. | ⤷ Try a Trial |
| China | 100391460 | ⤷ Try a Trial | |
| China | 1688312 | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof | ⤷ Try a Trial |
| Austria | 352300 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
